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Novel polymorphs of Lorlatinib and their processes for the preparation thereof 
Field of the invention:  
 The present invention provides novel polymorphs of (10R)-7-amino-12-fluoro-2,10, 
16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h] [2,5,11] 
benzoxa diazacyclotetradecine-3-carbonitrile represented by following structural formula-1 
and their processes for the preparation thereof. 
 
Formula-1 
Background of the invention: 
 (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-
methenopyrazolo[4,3h][2,5,11] benzoxadiazacyclotetradecine-3-carbonitrile is commonly 
known as Lorlatinib, which was approved in US & Europe under the brand names of 
Lorbrena and Lorviqua respectively  for the treatment of anaplastic lymphoma kinase (ALK)-
positive metastatic non-small cell lung cancer.  
 
Formula-1 
 Lorlatinib or pharmaceutically acceptable salts are described in US 8680111 B2. 
 US 9637500 B2 patent describes hydrated crystalline form 1, form 2 and acetic acid 
solvate form 3 of Lorlatinib and their process for the preparation. 
 WO2017175091A1 PCT publication describes crystalline anhydrous form 1 and 
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crystalline hydrate form 2 of Lorlatinib maleate and their processes for the preparation. 
 US 10420749 B2 patent describes anhydrous crystalline form-7 of Lorlatinib and its 
process for the preparation. 
 WO2019073347 A1 PCT publication describes hydrated crystalline form 24 of 
Lorlatinib and its process for the preparation. 
 WO2019209633A1 PCT publication describes crystalline form Z, form Ul, form U2, 
form Gamma, form Epsilon, form X, form El and form E2 of Lorlatinib and its fumarate 
form Fl, benzoate form Bl, nicotinate form Nl, mesylate form Sl, tosylate form Tl, 
hydrobromide form Hl, L-malate form Ll, citrate form Cl, L-tartarate form Rl and maleate 
forms Ml, M2, M4 and M5 and their process for the preparation. 
 There is a still develop further polymorphs of Lorlatinib to meet the 
pharmaceuticals requirements.    
Since the development of new polymorphic forms of an active pharmaceutical 
ingredient provides new opportunity to improve the performance characteristics of 
pharmaceutical finished product, the development of new polymorphic forms is always 
encouraged. 
Furthermore, solid state study of an active pharmaceutical ingredient aims to widen 
the variety of crystalline forms that a formulation scientist has available for designing a 
pharmaceutical dosage form with desired characteristics. 
 After numerous trials and earnest efforts, the present inventors found novel crystalline 
polymorphs of Lorlatinib, which are useful and suitable for the preparation of various 
pharmaceutical compositions. 
 
Brief description of the invention: 
The first embodiment of the present invention provides a novel crystalline form of 
Lorlatinib, herein after designated as crystalline form-M. 
 The second embodiment of the present invention provides a process for the 
preparation of crystalline form-M of Lorlatinib. 
The third embodiment of the present invention provides a novel crystalline form of 
Lorlatinib, herein after designated as crystalline form-S. 
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 The fourth embodiment of the present invention provides a process for the 
preparation of crystalline form-S of Lorlatinib.  
The fifth embodiment of the present invention provides a novel crystalline form of 
Lorlatinib, herein after designated as crystalline form-N. 
 The sixth embodiment of the present invention provides a process for the preparation 
of crystalline form-N of Lorlatinib. 
The seventh embodiment of the present invention provides a novel crystalline form of 
Lorlatinib, herein after designated as crystalline form-S1. 
 The eighth embodiment of the present invention provides a process for the 
preparation of crystalline form-S1 of Lorlatinib. 
The ninth embodiment of the present invention is to provide a process for the 
preparation of amorphous form of Lorlatinib. 
Brief description of the drawings: 
Figure-1: Illustrates the powder X-Ray diffraction pattern of crystalline form-M of 
Lorlatinib. 
Figure-2: Illustrates the powder X-Ray diffraction pattern of crystalline form-S of Lorlatinib. 
Figure-3: Illustrates the powder X-Ray diffraction pattern of crystalline form-N of 
Lorlatinib. 
Figure-4: Illustrates the powder X-Ray diffraction pattern of crystalline form-S1 of 
Lorlatinib. 
Figure-5: Illustrates the powder X-Ray diffraction pattern of amorphous form of Lorlatinib. 
Figure-6: Illustrates the powder X-Ray diffraction pattern of crystalline form-M of 
Lorlatinib obtained according to example-10. 
 
Detailed description of the invention: 
 As used herein the term “suitable solvent” or solvent used in the present invention 
refers to “hydrocarbon solvents” such as n-hexane, n-heptane, cyclohexane, pet ether, 
benzene, toluene, pentane, cycloheptane, methyl cyclohexane, ethylbenzene, m-, o-, or p-
xylene, or naphthalene and the like; “ether solvents” such as dimethoxymethane, 
tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, diethyl ether, ethylene glycol dimethyl 
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ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, diethylene glycol 
diethyl ether, triethylene glycol dimethyl ether, anisole, t-butyl methyl ether,  1,2-dimethoxy 
ethane and the like; “ester solvents” such as methyl acetate, ethyl acetate, isopropyl acetate, 
n-butyl acetate and the like; “polar-aprotic solvents such as dimethylacetamide (DMA), 
dimethylformamide (DMF), dimethylsulfoxide (DMSO), N-methylpyrrolidone (NMP) and 
the like; “chloro solvents” such as dichloromethane, dichloroethane, chloroform, carbon 
tetrachloride and the like; “ketone solvents” such as acetone, methyl ethyl ketone, methyl 
isobutylketone and the like; “nitrile solvents” such as acetonitrile, propionitrile, 
isobutyronitrile and the like; “alcohol solvents” such as methanol, ethanol, n-propanol, 
isopropanol, n-butanol, isobutanol, t-butanol, 2-nitroethanol, 2-fluoroethanol, 2,2,2-
trifluoroethanol, ethylene glycol, 1,2-propanediol (propylene glycol), 2-methoxyethanol, l, 2-
ethoxyethanol, diethylene glycol, 1, 2, or 3-pentanol, neo-pentyl alcohol, t-pentyl alcohol, 
diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol, or glycerol and the 
like; “polar solvents” such as water or mixtures thereof. 
 
 The first embodiment of the present invention provides a novel crystalline form of 
Lorlatinib herein after designated as crystalline form-M.  
In an aspect of first embodiment provides the crystalline form-M of Lorlatinib 
characterized by its Powder X-Ray diffractogram substantially in accordance with figure-1. 
 
The second embodiment of the present invention provides a process for the 
preparation of crystalline form-M of Lorlatinib, comprising: 
a) dissolving Lorlatinib in 2-butanol, 
b) isolating crystalline form-M of Lorlatinib. 
Dissolving the Lorlatinib in step-a) can be done at a temperature ranging from about 25°C to 
reflux temperature of the solvent used; isolating crystalline form-M in step-b) is by solvent 
removal by known techniques which are selected from filtration, cooling the mixture to lower 
temperatures to precipitate the solid followed by filtration of the mixture, crystallization; or 
by combining with an anti-solvent. 
In the above process, step a) or step-b) optionally involve seeding with crystalline 
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form-M of Lorlatinib. 
 
The third embodiment of the present invention provides a novel crystalline form of 
Lorlatinib, herein after designated as crystalline form-S.  
In an aspect of third embodiment provides the crystalline form-S of Lorlatinib 
characterized by its powder X-Ray diffractogram as illustrated in figure-2. 
 
The fourth embodiment of the present invention provides a process for the 
preparation of crystalline form-S of Lorlatinib, comprising: 
a) dissolving Lorlatinib in isopropanol, 
b) isolating crystalline form-S of Lorlatinib. 
Dissolving the Lorlatinib in step-a) can be done at a temperature ranging from about 25°C to 
reflux temperature of the solvent used; isolating crystalline form-S in step-b) is by solvent 
removal by known techniques which are selected from cooling the mixture to lower 
temperatures to precipitate the solid followed by filtration of the mixture, crystallization; or 
by combining with an anti-solvent, wherein anti-solvent is selected from water. 
In the above process, step a) or step-b) optionally involve seeding with crystalline 
form-S of Lorlatinib. 
 
The fifth embodiment of the present invention provides a novel crystalline form of 
Lorlatinib, herein after designated as crystalline form-N.  
In an aspect of fifth embodiment provides the crystalline form-N of Lorlatinib 
characterized by its powder X-Ray diffractogram as illustrated in figure-3. 
 
The sixth embodiment of the present invention provides a process for the preparation 
of crystalline form-N of Lorlatinib, comprising: 
a) dissolving Lorlatinib in ethanol, 
b) isolating crystalline form-N of Lorlatinib. 
Dissolving the Lorlatinib in step-a) can be done at a temperature ranging from about 25°C to 
reflux temperature of the solvent used; isolating crystalline form-N in step-b) is by solvent 
removal by known techniques which are selected from filtration, cooling the mixture to lower 
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temperatures to precipitate the solid followed by filtration of the mixture, crystallization; or 
by combining with an anti-solvent, wherein anti-solvent is selected from hydrocarbon 
solvents. 
In the above process, step a) or step-b) optionally involve seeding with crystalline 
form-N of Lorlatinib. 
 
The seventh embodiment of the present invention provides a novel crystalline form of 
Lorlatinib, herein after designated as crystalline form-S1.  
In an aspect of seventh embodiment provides the crystalline form-S1 of Lorlatinib 
characterized by its powder X-Ray diffractogram as illustrated in figure-4. 
 
The eighth embodiment of the present invention provides a process for the 
preparation of crystalline form-S1 of Lorlatinib, comprising: 
a) dissolving Lorlatinib in n-pentanol, 
b) isolating crystalline form-S1 of Lorlatinib. 
Dissolving the Lorlatinib in step-a) can be done at a temperature ranging from about 25°C to 
reflux temperature of the solvent used; isolating crystalline form-S1 in step-b) is by solvent 
removal by known techniques which are selected from filtration, cooling the mixture to lower 
temperatures to precipitate the solid followed by filtration of the mixture, crystallization; or 
by combining with an anti-solvent, wherein anti-solvent is selected from hydrocarbon 
solvents. 
In the above process, step a) or step-b) optionally involve seeding with crystalline 
form-S1 of Lorlatinib. 
 
The ninth embodiment of the present invention provided a process for the preparation 
of amorphous form of Lorlatinib comprises: 
a) dissolving Lorlatinib to a solvent, 
b) isolating the amorphous form of Lorlatinib. 
Dissolving the Lorlatinib in step-a) can be done at a temperature ranging from about 25°C to 
reflux temperature of the solvent used; solvent is selected from ketone solvents, ester 
solvents or mixtures thereof and the like; isolating amorphous form in step-b) is by solvent 
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removal by known techniques which are selected from distillation, filtration, cooling the 
mixture to lower temperatures to precipitate the solid followed by filtration of the mixture; or 
by combining with an anti-solvent selected from hydrocarbon solvents, water or mixtures 
thereof and the like. 
In an aspect of the ninth embodiment provides amorphous form of Lorlatinib 
characterized by its powder X-Ray difractogram substantially in accordance with figure-5. 
 
The crystalline form-M, form-S, form-N, form-S1 and amorphous form of Lorlatinib 
of the present invention are prepared by the processes as illustrated in the present invention 
and they are useful for the preparation of various pharmaceutical compositions formulated in 
a manner suitable for the route of administration to be used where at least a portion of 
Lorlatinib is present in the composition in particular polymorphic form mentioned.  
 An embodiment of the present invention provides the use of crystalline form-M, 
form-S, form-N, form-S1 and amorphous form of Lorlatinib for the preparation of 
pharmaceutical formulations.  
The other embodiment of the present invention provides pharmaceutical composition 
comprising crystalline form-M or form-N or form-S or form-S1 or amorphous of Lorlatinib 
or mixture thereof and at least one pharmaceutically acceptable excipient. As used herein, the 
term "pharmaceutical compositions" or "pharmaceutical formulations" include tablets, pills, 
powders, liquids, suspensions, emulsions, granules, capsules, suppositories, or injection 
preparations. 
In an aspect of the present invention provides a pharmaceutical composition 
comprising crystalline forms or amorphous prepared according to the present invention and 
one or more pharmaceutically acceptable carriers for the treatment of anaplastic lymphoma 
kinase (ALK)-positive metastatic non-small cell lung cancer. 
 
Crystalline forms or amorphous form of Lorlatinib obtained according to the present 
invention is having a purity of >98%, preferably >99%, more preferably >99.5% by HPLC. 
 
Crystalline forms or amorphous form of Lorlatinib produced by the processes of the 
present invention can be further micronized or milled to get desired particle size to achieve 
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desired solubility profile based on different forms of pharmaceutical composition 
requirements. Techniques that may be used for particle size reduction include but not limited 
to single or multi-stage micronization using cutting mills, pin/cage mills, hammer mills, jet 
mills, fluidized bed jet mills, ball mills and roller mills. Milling or micronization may be 
performed before drying or after drying of the product. 
 
Crystalline forms or amorphous form of Lorlatinib obtained according to the present 
invention has particle size of less than about 250 μm or less than about 200 μm or less than 
about 150 μm or less than about 100 μm or less than about 50 μm or any other suitable 
particle sizes. 
 
Lorlatinib used as an input for the preparation of crystalline forms or amorphous form 
of Lorlatinib obtained according to the present invention is prepared by any of the processes 
disclosed in literature such as US 8680111 B2 or other references. 
   
PXRD (Powder X-Ray diffractogram) Method of Analysis:  
The PXRD analysis of compounds of the present invention was carried out by using 
BRUKER-Axis/D8 ADVANCE (DAVINCI) X-Ray diffractometer using CuKα radiation of 
wavelength 1.5406A° and at a continuous scan speed of 0.03°/min. 
 
 The best mode of carrying out the present invention is illustrated by the below 
mentioned examples. These examples are provided as illustration only and hence should not 
be considered as limitation of the scope of the invention. 
 
Examples: 
Example-1: Preparation of crystalline form-M of Lorlatinib 
Dissolved Lorlatinib (500 mg) in 2-butanol (5 ml) at 95-100°C and stirred for 10 minutes at 
the same temperature. Cooled the solution to 0-5°C and stirred for 15 minutes at the same 
temperature. Filtered the precipitated solid and dried to get the title compound. 
Yield: 400 mg. PXRD of the obtained compound is as illustrated in figure-1. 
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Example-2: Preparation of crystalline form-S of Lorlatinib 
Dissolved Lorlatinib (1 g) in isopropanol (4 ml) at 80-85°C and stirred for 10 minutes at the 
same temperature. Water (200 µl) was added to resultant solution, cooled the mixture to 0-
5°C and stirred for 80 minutes at the same temperature. Filtered the precipitated solid and 
dried to get the title compound. 
Yield: 800 mg. PXRD of the obtained compound is as illustrated in figure-2. 
Example-3: Preparation of crystalline form-S of Lorlatinib 
Dissolved Lorlatinib (2 g) in isopropanol (10 ml) at 80-85°C and stirred for 10 minutes at the 
same temperature. Cooled the resultant solution to 25-30°C and stirred for 30 minutes at the 
same temperature. Filtered the precipitated solid and dried to get the title compound.  
Yield: 1.8 g. PXRD of the obtained compound is similar to figure-2. 
Example-4: Preparation of crystalline form-N of Lorlatinib 
Dissolved Lorlatinib (2 g) in ethanol (20 ml) at 25-30°C. The resultant solution was added to 
pre-cooled n-heptane (300 ml) at 0-5°C and stirred for 30 minutes at the same temperature. 
Filtered the precipitated solid and dried to get the title compound. 
Yield: 1500 mg. PXRD of the obtained compound is as illustrated in figure-3. 
Example-5: Preparation of crystalline form-S1 of Lorlatinib 
Dissolved Lorlatinib (2 g) in n-pentanol (100 ml) at 80-85°C. The resultant solution was 
added to pre-cooled n-heptane (300 ml) at 0-5°C and stirred for 20 minutes at the same 
temperature. Filtered the precipitated solid and dried to get the title compound. 
Yield: 1 g. PXRD of the obtained compound is as illustrated in figure-4. 
Example-6: Preparation of Amorphous form of Lorlatinib 
Dissolved Lorlatinib (500 mg) in 2-pentanone (1 ml) at 25-30°C. The resultant solution was 
cooled to 0-5°C. n-Heptane (30 ml) was added to the above solution at 0-5°C and stirred for 
90 minutes at the same temperature. Filtered the precipitated solid and dried to get the title 
compound. 
Yield: 460 mg. PXRD of the obtained compound is as illustrated in figure-5. 
Example-7: Preparation of Amorphous form of Lorlatinib 
Dissolved Lorlatinib (500 mg) in acetone (3 ml) at 25-30°C. The resultant solution was 
added to pre-cooled mixture of n-heptane and water (60 ml) at 0-5°C and stirred for 90 
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minutes at the same temperature. Filtered the precipitated solid and dried to get the title 
compound. 
Yield: 450 mg.  
Example-8: Preparation of Amorphous form of Lorlatinib 
Dissolved Lorlatinib (200 mg) in ethyl acetate (3 ml) at 70-75°C. The resultant solution was 
cooled to 0-5°C. n-Heptane (30 ml) was added to above solution at 0-5°C and stirred for 10 
minutes at the same temperature. Filtered the precipitated solid and dried to get the title 
compound. 
Yield: 150 mg. 
Example-9: Preparation of Amorphous form of Lorlatinib 
Dissolved Lorlatinib (200 mg) in methyl isobutyl ketone (3 ml) at 95-100°C. The resultant 
solution was cooled to 0-5°C. n-Heptane (30 ml) was added to above solution at 0-5°C and 
stirred for 10 minutes at the same temperature. Filtered the precipitated solid and dried to get 
the title compound. 
Yield: 150 mg.  
Example-10: Preparation of crystalline form-M of Lorlatinib 
Dissolved Lorlatinib (15 g) in 2-butanol (150 ml) at 95-100°C. Cooled the solution to 0-5°C 
and stirred for 1 hour at the same temperature. Filtered the precipitated solid and dried to get 
the title compound. 



























                                                                      Figure-2                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                            
 
12
: Novel polymorphs of Lorlatinib and their processes for the prepar
Published by Technical Disclosure Commons, 2020
12 
 





                                                                     
Figure-4 
                                                                                                                                                                                                                                  
                                                                                                            
 
13
















: Novel polymorphs of Lorlatinib and their processes for the prepar
Published by Technical Disclosure Commons, 2020
